Diffuse scleroderma
Drug research and approvals for diffuse scleroderma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 145 studies of diffuse scleroderma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 145
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 145 recruiting on ClinicalTrials.gov ↗- Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesNCT05029336 · Phase 2 · Stephan Grupp MD PhD · starts Nov 1, 2026
- Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)NCT07650565 · Not applicable · University Hospital, Montpellier · starts Oct 27, 2026
- FT839 in Autoimmune DiseasesNCT07800871 · Phase 1 / Phase 2 · Fate Therapeutics · starts Oct 1, 2026
- A Study of ATG-201 in Adult Participants With Autoimmune DiseasesNCT07732309 · Phase 1 · Antengene Biologics Limited · starts Sep 26, 2026
- A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it…NCT07649265 · Phase 1 · Otsuka Pharmaceutical Development & Commercialization, Inc. · starts Sep 24, 2026
- A Study to Test CRT-402 in Refractory Autoimmune DiseaseNCT07778446 · Phase 1 / Phase 2 · Myeloid Therapeutics · starts Aug 26, 2026
- A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisNCT07497087 · Phase 3 · Boehringer Ingelheim · starts Jul 27, 2026
- US Zamto-cel Autoimmune DiseasesNCT06708845 · Phase 1 · Miltenyi Biomedicine GmbH · starts Jul 1, 2026
- Immun4Cure Cohort of Autoimmune DiseasesNCT07515638 · Not reported · University Hospital, Montpellier · starts Jun 23, 2026
- Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive TherapyNCT07493395 · Phase 2 · University Hospital, Montpellier · starts Jun 11, 2026
Drug Pipeline
2 in phase 3, 13 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Lenabasum
- Phase 3
- Sildenafil
- Phase 3 Phosphodiesterase 5A inhibitor
- Brentuximab vedotin
- Phase 2 Tubulin inhibitor
- Mycophenolate mofetil
- Phase 2 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Human immunoglobulin g
- Phase 2 Replacement therapy, immunomodulatory effects
- Abatacept
- Phase 2 T-lymphocyte activation antigen CD86 inhibitor
- Belumosudil
- Phase 2 Rho-associated protein kinase 2 inhibitor
- Fipaxalparant
- Phase 2
- Methoxsalen
- Phase 2 DNA inhibitor
- Acetylcysteine
- Phase 2 Glutathione precursor
- Lanifibranor
- Phase 2 Peroxisome proliferator-activated receptor agonist
- Ianalumab
- Phase 2 Tumor necrosis factor receptor superfamily member 13C binding agent
- Dersimelagon
- Phase 2 Melanocortin receptor 1 agonist
- Asengeprast
- Phase 2
- Telitacicept
- Phase 2
- Rilonacept
- Phase 1 Interleukin-1 beta inhibitor
- Teprotumumab
- Phase 1 Insulin-like growth factor I receptor antagonist
- Fresolimumab
- Phase 1 Transforming growth factor beta-1 inhibitor
- AVID-200
- Phase 1
How Its Trials Ended
561 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 126 whose ending is known, 37% met their primary endpoint, 12% missed it and 52% stopped early.
- Completed, result not reported20336%
- Ongoing15227%
- Status unknown8014%
- Met its primary endpoint468%
- Stopped: other or unclear326%
- Stopped: enrollment or feasibility163%
- Missed its primary endpoint153%
- Stopped: sponsor or business decision81%
- Stopped: lack of efficacy61%
- Stopped: safety20%
- Stopped: funding10%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA